Testagen (KDE): experimental peptide studied for male reproductive aging
A lab-made peptide based on testicular tissue, studied in animals for boosting testosterone and sperm quality in aging males; experimental, not an approved drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
A chemistry service or a researcher ordered the sequence, it was manufactured, and mass spectrometry confirmed the right molecule was produced.
A binding or activity measurement confirmed that it actually does what the computer predicted — or didn't.
Snapshot
Class: Bioregulator peptide (Khavinson program, testicular tissue-targeted)
Evidence tier: Animal-only evidence
Status: No approved therapeutic status. Not FDA-, EMA-, MHRA-, or Health Canada-approved. Sold as a Russian-market dietary peptide complex and as a Western research chemical.
Best-supported effect: Improved testosterone output and sperm morphology markers in aged rodent models (Khavinson-program animal work; no independent Western replication)
Main caveat: Evidence base is among the thinnest in the Khavinson catalog — no PubMed-indexed human efficacy trials, no independent preclinical replication, and no structural validation of the proposed mechanism; claims framing Testagen as a testosterone therapy or TRT alternative significantly exceed what the available evidence supports
What this is
Testagen is a synthetic tetrapeptide bioregulator from the Khavinson program at the St. Petersburg Institute of Bioregulation and Gerontology, most commonly cited as the sequence Lys-Glu-Asp-Gly (KEDG). It occupies the testicular slot in the Khavinson organ-specific peptide catalog — positioned as the synthesized, chemically defined counterpart to the older natural-extract preparation Testoluten, which is derived from bovine testicular tissue. Within the Khavinson framework, Testagen is proposed to act on testicular gene expression to support Leydig cell function and spermatogenesis in aging males, paralleling the design rationale of sibling peptides Livagen (KEDA), Vesugen (KED), and Cortagen (AEDP) for their respective target tissues.
The peer-reviewed footprint specific to Testagen is unusually thin even by Khavinson-catalog standards. The clearest published sequence confirmation comes from a 2025 chemistry paper in Molecules that names H-Lys-Glu-Asp-Gly-OH as "Testagen peptide" while studying copper corrosion inhibition — a property entirely unrelated to the proposed testicular biology. The biological claims — Leydig cell steroidogenesis improvement, sperm morphology effects, and adjunct use in chronic abacterial prostatitis — rest on a small, mostly Russian-language, Khavinson-group-concentrated footprint that has not been independently replicated in Western andrology or reproductive-biology laboratories.
Evidence map
| Evidence layer | Grade | What it supports |
|---|---|---|
| Human | Anecdotal / not RCT-grade | One small uncontrolled Russian-language clinical study in men with chronic abacterial prostatitis and androgenic deficiency is cited in Khavinson-adjacent literature; not PubMed-indexed as a standalone Testagen RCT and does not meet controlled-trial standards. No PubMed-indexed human efficacy trials for hypogonadism, male infertility, or andropause exist. |
| Animal | Weak | Khavinson-group rodent work describes improved testosterone output (ex vivo) and sperm morphology parameters in aged male rats. Reports are concentrated in Russian-language gerontology journals; no independent non-Khavinson laboratories have published confirmatory animal work. |
| In vitro | None identified | No cell-based or receptor-binding assay data specific to Testagen's testicular biology are identified. A 2025 chemistry paper confirms the molecular identity and reports copper corrosion inhibition properties; this is not biological in vitro evidence. |
| Computational | None identified | The 2025 chemistry paper includes DFT and Monte Carlo modeling of copper-surface adsorption, not biological target prediction. No docking or structure-prediction data for testicular biology are attached. |
| Mechanism | Weak / proposed | Testagen is proposed to bind DNA regulatory regions and histone proteins in testicular cells, modulating chromatin accessibility and gene expression — including putative upregulation of StAR (steroidogenic acute regulatory protein). This model is borrowed from the broader Khavinson program framework; Testagen-specific structural characterization, receptor identification, or gene-expression profiling in Leydig cells has not been published in PubMed-indexed sources outside the originating group. |
The majority of the biological evidence originates from one research program (Khavinson group, St. Petersburg Institute of Bioregulation and Gerontology). Independent replication by Western andrology, reproductive biology, or gerontology laboratories is absent. This is a key limitation of the current evidence base.
Claim check
| Claim | Verdict | Evidence layer | Confidence |
|---|---|---|---|
| Improved testosterone output and sperm morphology in aged rodents | Supported (animal, Khavinson-group only) | Animal | Low — no independent Western replication; all animal data from originating program |
| Human efficacy for Leydig cell support or testosterone restoration | Not established | Human | Low — only a small uncontrolled Russian-language clinical study cited; no PubMed-indexed RCT |
| Adjunct benefit in chronic abacterial prostatitis with androgenic deficiency | Not established | Human | Low — source-cited Russian clinical work does not meet controlled-trial standards |
| Testagen as a testosterone therapy or TRT alternative | Not established | None | High — published literature explicitly states this claim significantly exceeds available evidence |
| Proposed direct peptide–DNA interaction mechanism in testicular cells | Not established | None | High — structural characterization and gene-expression profiling in Leydig cells are absent from PubMed-indexed sources; mechanism is extrapolated from broader program framework |
Experimental exposure
This section reports exposure used in animal experiments. It does not establish human dosing.
| Context | System | Experimental exposure | Duration | Endpoint | Limitation |
|---|---|---|---|---|---|
| Rodent aging model (Khavinson group) | Aged male rats | Testagen (dose and route details not individually extracted from available literature) | Not individually extracted | Testosterone output ex vivo; sperm morphology parameters | Single-program origin; no independent replication; dose-response and route not characterized in available Western-indexed sources |
Preclinical safety signals
| Signal | System | Notes |
|---|---|---|
| No significant adverse effects reported | Aged rodent models (Khavinson program) | Based on the small available Khavinson-program animal literature; duration and dose range are limited |
| Injection-site reactions | Potential concern with research-chemical supply | Research-chemical vials carry quality and sterility uncertainty; this signal is precautionary, not study-derived |
| Uncharacterized proliferative risk | Not studied | The proposed mechanism — modulation of gene expression in steroidogenic and spermatogenic cells — raises questions about unintended proliferative effects in prostate or testicular tissue; these have not been addressed in available animal models |
| Long-term safety | Not established | No chronic animal safety data; no human pharmacokinetic data; no systematic dose-finding; no reproductive-toxicology studies |
No formal human safety studies are present. Drug interactions with testosterone therapy, 5-alpha reductase inhibitors, aromatase inhibitors, and SERMs are uncharacterized.
Regulatory status
| Region / body | Status | Notes |
|---|---|---|
| US (FDA) | Not approved | Not approved for any indication; not recognized as a dietary supplement ingredient; not on the FDA list of peptides eligible for 503A compounding; sold as a research chemical labeled "not for human use" |
| EU (EMA) | Not approved | per available sources; no EMA approval identified |
| UK (MHRA) | Not approved | per available sources; not established as a prescription medicine |
| Canada (Health Canada) | Not approved | per available sources; not established as a prescription medicine |
| Russia | Sold as dietary peptide complex | Available under the Peptides.ru / Khavinson Peptides brand as an oral dietary peptide complex positioned as a functional food, not a registered prescription medicine; this is not Western regulatory approval |
| WADA | Status unclear — per available sources as potentially within S0 / S1 scope | Not specifically named on the WADA Prohibited List at time of available literature. Source notes that any agent credibly claimed to raise endogenous testosterone output sits within the spirit of the S1 anabolic-agents category, and injectable Testagen is reasonably read as falling under WADA S0 (substances not approved by any governmental regulatory health authority for human therapeutic use). per available sources status only — not independently verified against the current list. |
No approved therapeutic status has been identified in Western regulatory databases.
Mechanism
Testagen's proposed mechanism, as described in the Khavinson program literature, involves direct interaction of the short tetrapeptide (Lys-Glu-Asp-Gly) with DNA regulatory regions and histone proteins in testicular cells. The proposed effect is modulation of chromatin accessibility and gene expression — specifically in Leydig cells and in cells supporting the seminiferous tubules — with the goal of reactivating steroidogenic and spermatogenic gene programs that the program associates with age-related decline. Putative downstream targets include upregulation of StAR (steroidogenic acute regulatory protein) expression, which would theoretically support cholesterol translocation into the mitochondria and the first step of testosterone biosynthesis.
This framework is the same general model the Khavinson program applies across its organ-specific short peptide catalog. For the sibling peptide Livagen (KEDA), ex vivo chromatin-decondensation data in human lymphocytes have been published. Testagen-specific evidence — structural characterization of claimed DNA binding in testicular chromatin, identification of regulated gene sets in Leydig cells, or identification of a receptor or transporter mediating uptake into testicular cells — is essentially absent from PubMed-indexed sources outside the originating program. The 2025 Molecules paper that provides the clearest published sequence confirmation for Testagen studies the molecule's copper corrosion inhibition properties using DFT and Monte Carlo modeling; it contributes to molecular identity but not to the proposed testicular biology.
The proposed mechanism is plausible as a framework but is not independently validated for Testagen's specific claimed targets.
Chemistry
| Field | Value |
|---|---|
| Sequence | Lys-Glu-Asp-Gly (KEDG) |
| IUPAC / full name | H-Lys-Glu-Asp-Gly-OH |
| Length | 4 amino acids |
| Topology | Linear |
| Modifications | None described |
| Sequence confidence | Verified (confirmed by 2025 Molecules chemistry paper,, which explicitly names H-Lys-Glu-Asp-Gly-OH as "Testagen peptide") |
| Molecular weight | Not individually extracted from available literature |
| Formula | Not individually extracted from available literature |
| CAS | Not present in available literature |
The 2025 chemistry paper provides the clearest Western-indexed confirmation of the KEDG sequence identity. Molecular weight and formula are not individually extracted.
Open questions
- Human translation: No controlled human efficacy trials for any male reproductive or hormonal indication have been published in PubMed-indexed databases. Whether the rodent steroidogenesis and sperm morphology findings translate to human androgen levels, fertility endpoints, or subjective andropause symptoms in a controlled setting is entirely unresolved.
- Independent replication: All animal and clinical evidence in this card originates from the Khavinson program or its affiliated group. Independent replication by Western andrology, reproductive biology, or gerontology laboratories has not been published. This is the primary confidence-limiting factor for every claim on this card.
- Mechanism validation: The proposed direct peptide–DNA interaction in testicular cells, StAR upregulation, and tissue-selective uptake have not been structurally characterized or independently confirmed in peer-reviewed sources outside the originating program.
- Proliferative safety: The proposed mechanism — modulation of steroidogenic and spermatogenic gene expression — raises unaddressed questions about potential off-target proliferative effects in prostate or testicular tissue, particularly in individuals with risk factors for hormone-sensitive cancers. No animal or human data addressing this concern are present in available literature.
- Pharmacokinetics: No human or animal pharmacokinetic characterization (absorption, distribution, metabolism, excretion) is described in PubMed-indexed sources. Oral bioavailability of the intact tetrapeptide, half-life, and tissue distribution are unknown.
- Drug interactions: Interactions with testosterone replacement therapy, 5-alpha reductase inhibitors, aromatase inhibitors, SERMs, and other agents acting on the hypothalamic-pituitary-gonadal axis are entirely uncharacterized.
- Research-chemical quality: The peptide is available in Western markets as a research-chemical lyophilized powder of unverified purity. Quality, sequence identity, sterility, and absence of contaminants cannot be assumed from that supply chain.
▸3-letter notation
▸citationbibtex
@peptide{pep10944,
sequence = {KDE},
target = {},
author = {peptidemodel},
year = {2026},
status = {designed}
}